Provided by Tiger Trade Technology Pte. Ltd.

CSTONE PHARMA-B

5.385
-0.065-1.19%
Volume:5.44M
Turnover:29.21M
Market Cap:8.59B
PE:-17.11
High:5.545
Open:5.500
Low:5.250
Close:5.450
52wk High:13.150
52wk Low:4.010
Shares:1.60B
HK Float Shares:1.60B
Volume Ratio:0.81
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.315
ROE:-89.13%
ROA:-18.89%
PB:11.94
PE(LYR):-17.11
PS:27.32

Loading ...

Goldman Sachs Issues Post-ASCO Analysis, Reiterates Buy Rating on CStone with HK$9.44 Target

Stock News
·
Jun 02

CStone Pharmaceuticals Sets 23 June 2026 AGM; Seeks Approval for Director Re-election, 20% Issuance Mandate and Equity Awards to CEO

Bulletin Express
·
Jun 01

CStone Pharma to Seek Shareholder Nod for 20% Issue Mandate, 10% Buy-Back Capacity and CEO Equity Awards

Bulletin Express
·
Jun 01

CStone: ASCO 2026 Data Underscore Robust Efficacy and Safety of Trispecific Antibody CS2009; Phase III Global Trial Planned for Year-End

Bulletin Express
·
Jun 01

CStone presents ASCO data for CS2009 PD-1/VEGF/CTLA-4 trispecific antibody in lung, colorectal cancer trials

Reuters
·
Jun 01

A Look At CStone Pharmaceuticals (SEHK:2616) Valuation After Pralsetinib’s First Domestic Launch In China

Simply Wall St.
·
May 25

CStone Pharmaceuticals Plans Share Buyback

MT Newswires Live
·
May 13

CStone Announces Plan to Repurchase up to 136.45 Million Shares After ASCO Meeting

Bulletin Express
·
May 13

CSTONE PHARMA-B Announces Plan to Repurchase Up to 136 Million Shares

Stock News
·
May 13

CStone Pharmaceuticals - to Repurchase up to 136.5 Mln Shares in Open Market Under General Mandate

THOMSON REUTERS
·
May 13

CStone Pharmaceuticals plans market buyback of up to 136,450,133 shares

Reuters
·
May 13

CStone Pharmaceuticals Begins Commercial Distribution of Locally Manufactured Pralsetinib

MT Newswires Live
·
May 11

CSTONE PHARMA-B Initiates Nationwide Commercial Distribution of Locally Produced Pralsetinib Capsules

Stock News
·
May 11

CStone launches nationwide distribution of China-made pralsetinib; projects 2026 sales above RMB 0.30 billion

Bulletin Express
·
May 11

CStone expects 2026 pralesatinib capsule sales revenue to top CNY 300 million

Reuters
·
May 11

CStone Pharmaceuticals - Begins Nationwide Commercial Supply of Locally Manufactured Pralsetinib Capsules

THOMSON REUTERS
·
May 11

CStone Pharma Issues 124.23 Million New Shares in April, Expanding Share Base to 1.60 Billion

Bulletin Express
·
May 07

Stock Track | CStone Pharmaceuticals-B Plummets 5.17% Intraday on Share Placement Dilution and Widening Annual Losses

Stock Track
·
Apr 28

CSTONE PHARMA-B 2025年净亏损达4.37亿元,创新管线投入加速推进

Bulletin Express
·
Apr 27

CStone Pharmaceuticals publishes 2025 annual report

Reuters
·
Apr 27